Network Immunology is developing and owns intellectual property rights to AbstimX™, an immune system strengthening technology.
AbstimX™ has been demonstrated to prevent the development of inflammatory breast cancer, to prevent the development of inflammatory colitis, and to therapeutically treat egg allergy in mouse studies at a laboratory at the University of Toronto.
The technology involves combining components from multiple immune systems, to form an exceptionally strong immune system that protects against age-related degenerative diseases. The product itself is delivered through a series of intravenous infusions into the bloodstream.
This product has emerged from the network theory of adaptive immunity. Dr. Niels Jerne, a Danish immunologist, was awarded the Nobel Prize in 1984, largely for the discovery that the immune system is a cybernetic network of cells and antibodies with memory, much in the same way that the brain is a cybernetic neural network with memory. During Jerne's life, and subsequent to his passing away, a colleague of his, Dr. Geoffrey Hoffmann, now Chief Scientist of Network Immunology Inc., developed Jerne's network theory with extensive experimental testing with collaborators.
Network Immunology Inc. is pioneering the development of immunological technologies based on the immune network framework. Further, because the network framework explains the central regulating unit of the immune system, the framework has led to a technology and product, i.e. AbstimX™, that prevents against multiple immunological disorders.